Local Coverage Determination (LCD):
MolDX: APC and MUTYH Gene Testing (L36882)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>CONTRACT TYPE</th>
<th>CONTRACT NUMBER</th>
<th>JURISDICTION</th>
<th>STATE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01111 - MAC A</td>
<td>J - E</td>
<td>California - Entire State</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01112 - MAC B</td>
<td>J - E</td>
<td>California - Northern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01182 - MAC B</td>
<td>J - E</td>
<td>California - Southern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01211 - MAC A</td>
<td>J - E</td>
<td>American Samoa</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01212 - MAC B</td>
<td>J - E</td>
<td>Guam</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01311 - MAC A</td>
<td>J - E</td>
<td>Hawaii</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01312 - MAC B</td>
<td>J - E</td>
<td>Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01911 - MAC A</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01912 - MAC B</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
</tbody>
</table>

LCD Information

Document Information

LCD ID

Original Effective Date

Created on 02/06/2020. Page 1 of 6
LCD Title
MolDX: APC and MUTYH Gene Testing

Proposed LCD in Comment Period
N/A

Source Proposed LCD
DL36882

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com.

CMS National Coverage Policy
Title XVIII of the Social Security Act, §1862(a)(1)(A). Allows coverage and payment for only those services that are
considered to be reasonable and necessary.


CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

This policy provides Medicare coverage for APC and MUTYH gene testing for individuals suspected to have Familial Adenomatous Polyposis (FAP), Attenuated FAP (AFAP) or MYH-associated polyposis (MAP) with a personal history of ≥20 adenomas over a lifetime.

Summary of Evidence

FAP and AFAP are autosomal dominant syndromes caused by a germ-line mutation in the APC gene. The distinction between FAP and AFAP is largely based on the number of polyps present. Individuals with >100 are said to have FAP, while those with <100 are said to have AFAP. FAP affected individuals generally develop adenomas throughout the colon beginning in their teens, whereas individuals with AFAP frequently have a right-sided distribution to polyps. The average age of symptomatic FAP diagnosis ranges from 35-45 years of age\(^1\). The clinical expression of AFAP is more variable with adenomas developing at a later age, and some patients with <10 cumulative adenomatous polyps\(^2\) . With nearly 100% penetrance of the APC gene, colorectal cancer (CRC) is inevitable in patients with FAP if colectomy is not performed. The cumulative risk of CRC cancer in AFAP is estimated to be nearly 70% at age 80\(^3\), with up to 30% of cancers occurring over age 40\(^4\). The average age of CRC diagnosis is >50 years for AFAP. FAP accounts for up to 1% of colorectal cancers.

Additional findings may be associated with classical FAP including congenital hypertrophy of retinal pigment epithelium (CHRPE); osteomas, supernumerary teeth, and odontomas; desmoids and epidermoid cysts; duodenal and other small bowel adenomas; gastric fundic gland polyps; and increased risk for medulloblastoma, papillary carcinoma of the thyroid and hepatoblastoma; and pancreatic, gastric and duodenal cancers. Although upper GI findings, thyroid and duodenal cancer risks are similar to classical FAP, other extraintestinal manifestations, including CHRPE and desmoids are unusual in AFAP.

Mutations in the MUTYH gene cause MUTYH-Associated Polyposis syndrome (MAP). Affected individuals have large numbers of adenomatous polyp, similar to patient with AFAP, and a high risk for CRC. The average age of patients with MAP-associated CRC is >50 years, with nearly 25% of patients diagnosed after age 60\(^6\). Individuals with MUTYH mutations also may develop extra-colonic findings including duodenal polyps and duodenal cancer.

Treatment and surveillance recommendations for FAP, AFAP and MAP are available in the current NCCN Genetic/Familial High-Risk Assessment: Colorectal guidelines\(^5\).

Analysis of Evidence

(Rationale for Determination)

Created on 02/06/2020. Page 3 of 6
Based on the results of multiple studies and the surveillance and treatment recommendations of at least one national society guideline, APC and MUTYH gene testing is reasonable and necessary for individuals suspected to have Familial Adenomatous Polyposis (FAP), Attenuated FAP (AFAP) or MYH-associated polyposis (MAP) with a personal history of ≥20 adenomas over a lifetime.

**General Information**

**Associated Information**

N/A

**Sources of Information**

N/A

**Bibliography**


<table>
<thead>
<tr>
<th>REVISION HISTORY DATE</th>
<th>REVISION HISTORY NUMBER</th>
<th>REVISION HISTORY EXPLANATION</th>
<th>REASON(S) FOR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2019</td>
<td>R5</td>
<td>The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</td>
<td>Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.)</td>
</tr>
<tr>
<td>11/01/2019</td>
<td>R4</td>
<td>11/01/2019: This LCD is being revised in order to adhere to CMS requirements per Chapter 13, Section 13.5.1 of the Program Integrity Manual, to remove all coding from LCDs. There has been no change in coverage with this LCD revision. Regulations regarding billing and coding were removed from the CMS National Coverage Policy section of this LCD and placed in the related Billing and Coding: MolDX: APC and MUTYH Gene Testing A57352 article. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage.</td>
<td>Provider Education/Guidance</td>
</tr>
<tr>
<td>11/01/2019</td>
<td>R3</td>
<td>As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD.</td>
<td>Revisions Due To Code Removal</td>
</tr>
<tr>
<td>05/15/2017</td>
<td>R2</td>
<td>LCD is revised to add CPT 81401. Note that 81401 was inadvertently left out of the draft and final LCDs.</td>
<td>Creation of Uniform LCDs Within a MAC Jurisdiction</td>
</tr>
<tr>
<td>05/15/2017</td>
<td>R1</td>
<td>LCD is revised to add ICD-10 code D12.0, effective 5/12/17 and to add the following required fields: Summary of the Evidence, Bibliography and Analysis of Evidence.</td>
<td>Creation of Uniform LCDs With Other MAC Jurisdiction Revisions Due To ICD-10-CM Code Changes</td>
</tr>
</tbody>
</table>

Associated Documents

Created on 02/06/2020. Page 5 of 6
Attachments
N/A

Related Local Coverage Documents
Article(s)
A57352 - Billing and Coding: MolDX: APC and MUTYH Gene Testing
A55463 - Response to Comments: MolDX: APC and MUTYH Gene Testing

LCD(s)
DL36882
- (MCD Archive Site)

Related National Coverage Documents
N/A

Public Version(s)
Updated on 01/28/2020 with effective dates 11/01/2019 - N/A
Updated on 12/03/2019 with effective dates 11/01/2019 - N/A
Updated on 10/07/2019 with effective dates 11/01/2019 - N/A
Updated on 05/22/2018 with effective dates 05/15/2017 - 10/31/2019
Updated on 08/14/2017 with effective dates 05/15/2017 - N/A
Updated on 03/17/2017 with effective dates 05/15/2017 - N/A

Keywords
N/A